Cladribine as oral treatment for multiple sclerosis

June 11, 2019 0 By FM

Cladribine (Mavenclad) has been granted approval to treat relapsing forms of multiple sclerosis (MS) in adults by the USFDA.

Cladribine is not recommended for MS patients with clinically isolated syndrome. Because of its safety profile, the use of the drug is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, an alternate drug indicated for the treatment of MS.

The efficacy of cladribine was shown in a clinical trial in 1,326 patients with relapsing forms of MS who had at least one relapse in the previous 12 months. The drug significantly decreased the number of relapses experienced by these patients compared to placebo.

Cladribine also reduced the progression of disability compared to placebo.